Hepatitis Social Community
FDA OKs Hep C Indication for Promacta
About This Community:

This forum is for hepatitis patients, family members, loved ones, friends or anyone with an interest in hepatitis, to have open social conversations about any topic they choose, with the exception of religion and politics. Please note that our standard “Rules for Posting in Public Areas”, which are found in our Terms of Use , also apply in this community. If you are newly diagnosed with Hepatitis or you have questions or information to share about current treatments, research studies, clinical trials, or other medical issues pertaining to Hepatitis, please post it in one of our Hepatitis Communities ( Hep A , Hep B , Hep C or Hep-autoimmune ).

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

FDA OKs Hep C Indication for Promacta

FDA OKs Hep C Indication for Promacta
By David Pittman, Washington Correspondent, MedPage Today
Published: November 23, 2012

WASHINGTON -- The FDA has approved eltrombopag (Promacta) for the additional indication of treating low blood platelet counts in patients with chronic hepatitis C.

The treatment will allow those patients who are otherwise poor candidates because of their platelet counts to undergo interferon-based therapy for the liver disease.

The drug was approved in November 2008 to treat low platelet counts -- idiopathic thrombocytopenia purpura -- in chronic sufferers who have had insufficient response to other drugs.

However, eltrombopag should not be used to normalize platelet counts in hepatitis C patients, its manufacturer, GlaxoSmithKline (GSK), said Monday. It should only be used in patients with chronic hepatitis C whose condition prevents them from starting interferon therapy.

Also, safety and efficacy haven't been established in combination with direct-acting antivirals.

Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet count by increasing megakaryocyte differentiation and proliferation. The FDA based its decision on two phase III randomized, double-blinded, controlled studies of more than 1,500 patients with platelet counts less than 75,000.

Overall, 66% of patients treated with eltrombopag plus peginterferon alpha 2a (Pegasys) and ribavirin had an early virologic response, compared with 50% of patients who received peginterferon 2a, ribavirin, and a placebo (P<0.0001), study results found. Additionally, 23% of the eltrombopag group achieved a sustained virologic response versus 14% of the placebo group (P=0.0064).

Eltrombopag carries a boxed warning of causing hepatotoxicity. The drug, in combination with interferon and ribavirin in hepatitis C patients, may increase the risk of hepatic decompensation, the FDA said.

GSK said common side effects in the two trials included anemia, pyrexia, fatigue, and to a lesser extent, peripheral edema.

The drug, known as Revolade outside the U.S., is marketed in 90 countries.


hector
1815939_tn?1377995399
Thanks for posting that article, Hector.
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis Social Community Resources
RSS Expert Activity
233488_tn?1310696703
Blank
New Cannabis Article from NORTH Mag...
Jul 20 by John C Hagan III, MD, FACS, FAAOBlank
242532_tn?1269553979
Blank
3 Reasons Why You are Still Binge E...
Jul 14 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Emotional Eating: What Your Closet ...
Jul 09 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
163305_tn?1333672171
Blank
orphanedhawk
Rural Mural, CA
317787_tn?1373214989
Blank
Dee1956
DC
96938_tn?1189803458
Blank
FlGuy
South, FL
1815939_tn?1377995399
Blank
pooh55811
446474_tn?1404424777
Blank
HectorSF
CA
Avatar_f_tn
Blank
dontworry_behappy1